Ionis Q2 2023 revenue up 40% to $188M; eplontersen PDUFA set for Dec 22, 2023

IONIS PHARMACEUTICALS INC

2023-Q2 EPS reported -$1.47 revenue$318,935,000

Total revenue $188M in Q2 (+40% YoY); operating loss $91M GAAP, $64M non-GAAP.
Cash & short-term investments $2.4B; issued $575M notes due 2028 at 1.75%, repurchased $434M of 2024 notes.
Eplontersen Phase 3 shows improvement through 85 weeks; PDUFA date Dec 22, 2023.
Donidalorsen OASIS-HAE and eplontersen CARDIO-TTRansform enrollment complete; data H1:2024 and H1:2025.
SPINRAZA royalties flat at $61M in Q2; Biogen's QALSODY approved for SOD1-ALS.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

IONIS PHARMACEUTICALS INC reported financial results for second quarter 2023; six months ended June 30, 2023.

Period: second quarter 2023; six months ended June 30, 2023
Result: reported results

Exact text from the filing

Ionis reports second quarter 2023 financial results

View on SEC.gov

Browse all earnings releases →

IONIS PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001140361-23-038715

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.